Infusion services continues to attract investor attention as the sector benefits from site-of-care migration trends, payer preference for lower-cost settings, and an expanding pipeline of infusible therapies.
In Cascadia Capital’s Infusion Services Insights report, our Healthcare team highlights recent transaction activity, reimbursement compression risks by specialty and drug, and the growing private equity presence across home, ambulatory, and office-based infusion platforms.
If you are a business owner, operator, or investor active in infusion services and would like to learn more about the sector or discuss how Cascadia can support your strategic goals, we would welcome the conversation.
To request a copy of the report, please contact Josh Mastracci.
